Top in endocrinology: Vitamin D3 and fracture risk, bone loss in young women
Click Here to Manage Email Alerts
A new analysis of the VITAL trial showed that vitamin D3 supplementation did not significantly reduce fracture risk compared with placebo in adults without vitamin D deficiency or osteoporosis. It was the top story in endocrinology last week.
Another top story was about an ongoing study following young women from childhood to adulthood that found bone loss may start as soon as 5 years after menarche, regardless of healthy behaviors.
Read these and more in endocrinology below:
VITAL: No fracture risk reduction with supplemental vitamin D
Vitamin D3 supplementation did not reduce fracture risk in a large cohort of U.S. adults not selected for vitamin D deficiency or osteoporosis, according to an ancillary analysis of the VITAL trial. Read more.
BMD loss seen in early adulthood for women, despite healthy behaviors
A menarche-centered model assessing age at peak bone mineral density suggests bone loss in women may begin as soon as 5 years after menarche, even among athletes, according to an analysis of longitudinal data. Read more.
Intersection between heart and liver a rapidly evolving field
About 25% of U.S. adults have nonalcoholic fatty liver disease, which is the most common chronic liver condition in the U.S., according to the American Liver Foundation. Read more.
Year in review: Five studies changing thyroidology practice
In an update on notable, recently conducted thyroid studies, a speaker reviewed the latest treatments and imaging modalities for children and adults that have the potential to change thyroidology practice. Read more.
Authorized generic drugs ‘insufficient’ to improve affordability in Medicare Part D
Authorized generic drugs for insulin and direct-acting antiviral agents may lower out-of-pocket spending for patients but are unlikely to provide savings for Part D plans or Medicare, data show. Read more.